The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

NUS

Nu Skin Enterprises, Inc.

Consumer Defensive · Household & Personal Products

Overall research band Very weak
Quality Very weak
Valuation Weak
Balance sheet Very weak
Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

Nu Skin Enterprises, Inc. is a global company focused on the creation and distribution of beauty and wellness solutions. Its main products include advanced skincare systems such as the ageLOC Spa and ageLOC Transformation lines, skincare devices like the ageLOC LumiSpa and ageLOC Boost, as well as a variety of cosmetic and personal care items. In addition, Nu Skin offers health and nutrition products, including ageLOC Youth, LifePak, ageLOC Meta nutritional supplements, ageLOC TR90 weight management programs, and Beauty Focus Collagen+ supplements. The company invests in research and development for its skincare and nutritional supplement portfolios. Nu Skin markets its products under proprietary brands such as Nu Skin, Pharmanex, and ageLOC, reaching customers through direct-to-consumer sales, independent distributors, retail stores and customer service centers in Mainland China, and its e-commerce platform.

The current research profile is Mixed Setup, with weak market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC8.0%Model input; read with the evidence status and period context.
Operating margin5.7%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years-13.8%Model input; read with the evidence status and period context.
FCF margin2.9%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.